comparemela.com

Latest Breaking News On - Hansa biopharma ab - Page 1 : comparemela.com

Hansa Biopharma: increase in number of shares and votes

/PRNewswire/ Hansa Biopharma AB (publ), ("Hansa" or the "Company") (STO: HNSA) today announced that the company s registered share capital and number of.

Prnewswire hansa biopharmaStephanie kenneyEvan ballantyneVp global corporate affairsHansa biopharmaChief financialHansa biopharma ab

Evan Ballantyne to join Hansa Biopharma as Chief Financial Officer

/PRNewswire/ Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), today announced the appointment of Evan Ballantyne as Chief Financial Officer (CFO),.

United statesUnited kingdomBritish columbiaPrnewswire hansa biopharmaStephanie kenneyDonato spotaEvan ballantyneKlaus sindahlHansa biopharmaHansa executive committeePreveceutical medical incHonors business administrationUniversity of windsorGain therapeutics incVp global corporate affairsUniversity of western ontario

Hansa Biopharma Year-end report January-December 2023

/PRNewswire/ Hansa Biopharma, the pioneer in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced its business update and.

United statesHansa biopharmaKlaus sindahlHitto kaufmannMedison pharmaMatthew shaulisPrnewswire hansa biopharmaDonato spotaStephanie kenneyEurotransplant desensitization programNewbridge pharmaceuticalsAcceptable mismatch programVp global corporate affairsDesensitization programDuchenne muscular dystrophyMiddle east

Imlifidase demonstrated positive safety, tolerability, and early efficacy outcomes in 15-HMedIdeS-09 phase 2 trial in Guillain-Barré Syndrome (GBS)

/PRNewswire/ Hansa Biopharma, "Hansa" (NASDAQ Stockholm: HNSA), today announced positive high-level data from the 15-HMedIdeS-09 phase 2 trial that.

United kingdomKlaus sindahlShahram attarianVan doornAchim kaufholdStephanie kenneyHansa biopharmaDrug administrationInternational coordinating principal investigatorVp global corporate affairsInternational guillain barrEuropean medicines agencyHead of department neuromuscular diseasesChief medical officerNeuromuscular diseasesHopitaux universitaires de marseille

Imlifidase demonstrated 90% patient survival and 82% graft survival at five years in extended pooled analysis with data from 17-HMedIdeS-14 study

/PRNewswire/ Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, today announced results.

United statesUppsala lanLos angelesStanley jordanHansa biopharmaStephanie kenneyTomas lorantPrnewswire hansa biopharmaKlaus sindahlSinai medical centerUppsala university hospitalHmedides clinical trial programEuropean unionEuropean medicines agencyAmerican kidney fundVp global corporate affairs

vimarsana © 2020. All Rights Reserved.